Our initiatives advance treatments for patients of all ages across brain tumor types.

Immunotherapy is an emerging type of cancer treatment strategy that aims to harness the body’s own immune system to detect and destroy tumor cells – just as it would a virus. It is one of the key areas of NBTS research funding.

Precision medicine is understanding the specific biological, genetic, and/or molecular characteristics driving a patient’s tumor growth and finding or developing drugs to target those particular molecular abnormalities that are responsible for the disease.

Cancer researchers have long known that the metabolism of tumor cells is different from the metabolism of healthy cells. As part of this process, tumors undergo a major shake-up to how their cells consume and utilize the fuel they need to sustain their growth and progression.

This initiative creates a centralized landing place where all ependymoma stakeholders can join together and support research, advocacy, and patient education initiatives for this rare tumor.

GBM AGILE (Glioblastome Adaptive Global Innovative Learning Environment) is the world’s first “adaptive clinical trial platform.” The purpose is to evaluate multiple investigational treatments for either newly diagnosed or recurrent glioblastoma to determine if any of these study treatment(s) improve overall survival as compared to standard treatments.

Quality of life (QoL) is a major concern among people living with a malignant or non-malignant brain tumor as well as family and other care partners who experience their own QoL needs as they care for their loved ones.